Intra-Articular Bevacizumab for Preventing Recurrent Hemarthrosis in Hemophilia With Chronic Synovitis
Efficacy of Intra-Articular Bevacizumab in Preventing Recurrent Hemarthrosis in Hemophilia Patients With Chronic Synovitis: A Pre- and Post-Design Study
Khyber Medical University Peshawar
25 participants
Sep 9, 2025
INTERVENTIONAL
Conditions
Summary
Hemophilia is an inherited bleeding disorder characterized by deficiency of clotting factors, leading to increased bleeding tendencies. The most common complications are joint bleeds (hemarthroses), which cause chronic changes in joints and ultimately disability. Recurrent hemarthroses often result from chronic synovitis in target joints of patients with hemophilia, a process driven by Vascular Endothelial Growth Factor (VEGF) mediated pathological angiogenesis. Intra-articular administration of Bevacizumab, a VEGF neutralizing monoclonal antibody, may block this process and reduce the frequency of recurrent joint bleeds. This study evaluates the efficacy and safety of intra-articular Bevacizumab for preventing recurrent hemarthrosis in patients with hemophilia and chronic synovitis.
Eligibility
Inclusion Criteria5
- Confirmed diagnosis of Hemophilia A.
- Presence of one or more target joints (knee, elbow, ankle) with chronic synovitis and a history of \>2 hemarthrosis episodes in the past 6 months.
- Target joint World Federation of Hemophilia (WFH) joint score of 2-3.
- Adequate hematological, renal, and liver function (as specified by protocol lab values).
- Ability and willingness to provide informed consent and comply with the study protocol.
Exclusion Criteria6
- HIV positive diagnosis.
- Severely damaged joints or anatomical limitations preventing safe injection.
- Contraindications to MRI.
- Uncontrolled hypertension.
- Recent major surgery/trauma (\<28 days).
- Serious non-healing wound, active cardiovascular disease, or other significant comorbidities that could increase risk or interfere with the study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
This clinical trial investigates the intra-articular injection of Bevacizumab, a recombinant humanized monoclonal antibody that inhibits Vascular Endothelial Growth Factor (VEGF). The intervention functions by binding to and neutralizing VEGF-A, thereby blocking the pathogenic angiogenesis and vascular permeability that characterizes chronic hemophilic synovitis. For administration, the first four patients will receive a dose of 20 mg in 0.8 mL per injection, and if this is well-tolerated without major toxicities, the dose for all subsequent patients will be increased to 40 mg in 1.6 mL. Each injection will be administered directly into the target joint (knee, elbow, or ankle) once every 28 days for a total of four doses. Crucially, all injections will be performed only after appropriate prophylactic factor replacement to mitigate any procedure-related bleeding risk.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07187661